ECPC Annual General Meeting 2015
From 19th to 21st June 2015
“Early birds” ECPC Travel Booking
ECPC awards your early commitment: apply now and ECPC books your travel!
From the 20th December to the 28th February ECPC Members can apply for full travel expense coverage to Brussels. The ECPC Members awarded will be provided directly by ECPC with tickets/travel arrangements to participate to the AGM (flight or train or bus, economy class, one travel grant per ECPC Member).
ECPC will awards the travel grants on a “first come – first served” basis, until the funds allocated will be depleted.
Only one representative (individual) per ECPC Member can apply.
ECPC will prioritise applications from:
- smaller ECPC Members (local, regional groups, rare cancers);
- Eastern and Southern Europe Member States;
- Non EU-Member States.
ECPC retains the final decision over the awarding of the travel grants.
ECPC Members that will register after the 28th February will have their accommodation covered and travel expenses reimbursed.
The reimbursement will be performed after the 2015 AGM upon submission of the original tickets/proof of payments, up to 200 EUR.
Decide the topics of ECPC 2015 AGM
Help us creating YOUR Annual General Meeting: participate to the survey and chose now the topics to be discussed during ECPC 2015 AGM in Brussels.
European cancer patients face many issues due to their condition. No one knows those issues better than ECPC Members, which help some of the 10 million European cancer patients overcome their problems with passion, dedication and competence.
ECPC appeals exactly to you passion, dedication and competence to decide which topic to discuss during our next Annual General Meeting, which will take place in Brussels from the 25th to the 28th June. Our experienced and expert Board Members selected 10 topics that you can rank according to your interests and needs. The results of the survey will be used to draft the ECPC AGM Programme.
The shortlisted topics are:
- Access to treatment (including access to innovative and essential cancer drugs, access to radiotherapy);
- Cross Border Healthcare Directive;
- Early diagnosis;
- Health Technology Assessment;
- Long term survivorship issues;
- Paediatric Oncology;
- Patients’ role in cancer research;
- Rare cancers.